
Strategic consulting support and fractional medical affairs leadership provide essential assistance to Australian pharma consulting teams as they manage limited resources and increasing demands. Our flexible contract medical affairs solutions offer expertise without the need for long-term commitments.
Australian medical affairs teams are increasingly responding to rising demands — from shaping evidence strategy and guiding launch decisions, to managing promo review and compliance. With a frozen headcount, it's common for priorities to stall.
PharmaVerse specializes in Australian pharma consulting by offering fractional medical affairs leadership and short-term contract medical affairs solutions that effectively clear backlogs and accelerate priorities. With decades of experience in medical affairs across Australia and global markets, our team is equipped to help you maintain compliance and credibility, ensuring your affiliate remains aligned with global strategies and timelines.


We tackle critical backlogs—ranging from promo reviews to SOPs—through our Australian pharma consulting services. With senior oversight on a short-term contract basis, including fractional medical affairs leadership, we ensure nothing slips through the cracks.

We’re your interim medical director, associate medical director, or medical manager on a short-term contract, providing peer-level strategic input through our Australian pharma consulting services, all while avoiding FTE costs associated with traditional medical roles. This approach ensures effective fractional medical affairs leadership without the long-term commitment.

We engage respected KOLs on a short-term contract as part of our Australian pharma consulting services to align endpoints, comparators, and real-world evidence with TGA, PBAC, or MSAC expectations through our contract medical affairs and fractional medical affairs leadership approach.
We tackle critical backlogs—ranging from promo reviews to SOPs—through our Australian pharma consulting services. With senior oversight on a short-term contract basis, including fractional medical affairs leadership, we ensure nothing slips through the cracks.
We’re your interim medical director, associate medical director, or medical manager on a short-term contract, providing peer-level strategic input through our Australian pharma consulting services, all while avoiding FTE costs associated with traditional medical roles. This approach ensures effective fractional medical affairs leadership without the long-term commitment.
We engage respected KOLs on a short-term contract as part of our Australian pharma consulting services to align endpoints, comparators, and real-world evidence with TGA, PBAC, or MSAC expectations through our contract medical affairs and fractional medical affairs leadership approach.
We engage trusted KOLs to uncover clinical insights, pressure-test evidence, and build advocacy ahead of PBAC/MSAC, leveraging our expertise in Australian pharma consulting and contract medical affairs, as well as offering fractional medical affairs leadership.
Fit-for-purpose SOPs from Australian pharma consulting that make compliance seamless, supported by contract medical affairs and fractional medical affairs leadership.
Evidence packages, comparators, and pathways tailored for PBAC, MSAC, and TGA — our Australian pharma consulting services have a trusted track record in supporting submissions. We also specialize in contract medical affairs and provide fractional medical affairs leadership to enhance your project's success.
IQVIA 2023 Launch Excellence VIII White Paper
PharmaVerse helps teams change the odds in the competitive landscape of Australian pharma consulting. We partnered with a rare disease sponsor facing MSAC rejections to strengthen their evidence and secure Highly Specialised Therapy funding. With over 15 years of experience in contract medical affairs and fractional medical affairs leadership, we are trusted by biotech sponsors and local affiliates alike.
Please reach us at medical@pharmaverse.com.au if you cannot find an answer to your question.
We act as your interim medical affairs team, providing senior expertise (e.g., medical director support) on-demand, without FTE costs, to clear backlogs and drive launches.
Yes, our team is well-versed in the Medicines Australia Code of Conduct, ensuring promotional reviews align with the Code and relevant TGA standards, thereby protecting your brand.
Depending on the volume and complexity, we can clear backlogs in 2-4 weeks via targeted reviews. Book a call to discuss scope and timelines.
We leverage local networks to engage trusted KOLs, boosting advocacy and HCP buy-in
Our flexible short-term contract model is cost-effective, tailored to your needs. Book a call to discuss scope and timelines.
References: IQVIA. (2023). In pursuit of medical launch excellence: Lessons for medical affairs from IQVIA’s Launch Excellence research (Launch Excellence VIII White Paper). This white paper offers valuable insights for Australian pharma consulting, highlighting key aspects of contract medical affairs and fractional medical affairs leadership. IQVIA. https://www.iqvia.com/-/media/iqvia/pdfs/library/white-papers/iqvia-launch-excellence-viii.pdf